PeptiDex
Peptide Research Index
Research-backed
Peptide Research Index
⚠️ Educational only · Not medical advice · Consult a doctor · Most peptides are research-only / not FDA-approved for human use
⚠️ Educational only · Not medical advice · Consult a doctor · Most peptides are research-only / not FDA-approved for human use
Also: LY3437943
🔥Triple Agonist (GLP-1/GIP/Glucagon)Multi-receptor activation for appetite suppression, fat oxidation, energy expenditure. Unique triple agonism at GLP-1, GIP, and glucagon receptors delivers synergistic metabolic effects unmatched by single or dual agonists.
Jastreboff et al. (NEJM): Phase 2 RCT showing 24.2% body weight reduction at 12mg dose over 48 weeks the highest reported weight loss in any obesity drug trial to date.
strongFirst-in-human Phase 1 trial demonstrating dose-dependent weight loss, favorable safety profile, and significant HbA1c reductions across multiple dose levels.
moderatePhase 2 sub-study showing retatrutide significantly reduces liver fat content, with ~90% of participants with baseline steatosis achieving resolution at 48 weeks.
strongReview of the triple agonism mechanism: GLP-1 provides appetite suppression, GIP enhances GH-like metabolic effects, and glucagon drives energy expenditure and hepatic lipid oxidation.
moderateGI side effects (nausea, diarrhea) common; investigational not FDA-approved as of 2026. Phase 3 TRIUMPH trials ongoing.
⚠️ For educational purposes only. Not medical advice. Consult a healthcare professional before using any peptide.
Investigational. Phase 2 doses: 1-12mg weekly with dose escalation. Not commercially available.
Last updated: 2026-01 · Laws change frequently. Verify current status in your jurisdiction.
Week 1
GI adjustment; nausea during dose escalation
Weeks 2-4
Rapid appetite reduction; early weight loss 1-2 lbs/week
Month 2-3
10-15% body weight reduction at therapeutic dose
Long-term
Up to 24.2% weight loss at 48 weeks (NEJM Phase 2 trial, 12mg dose)
| Side Effect | Incidence | Severity |
|---|---|---|
Nausea From Phase 2 trial; most pronounced during escalation | ~45% of users | moderate |
Diarrhea | ~25% of users | mild |
Vomiting | ~20% of users | moderate |
Constipation | ~20% of users | mild |
Incidence rates sourced from published clinical trial data where available; otherwise based on community research observations.
Maximize fat loss while preserving or building lean muscle the gold standard for total body transformation
Maximum fat loss through multi-pathway metabolic optimization
Weekly Peptide Research
New studies · vendor alerts · protocol tips
No spam. Unsubscribe anytime. Research use only.